SGRL629.00

Shree Ganesh Remedies Limited

· Pharma & Health
AnnualQuarterly₹ CrorePeersBPLPHARMAJENBURPHKPLMAKERSLNOVARTINDPARNAXLABSHUKRAPHARSUNLOC
View
In ₹ Crore except Per Share
12 Months Ending
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Revenue from Operations125.9108.6109.3
Other Income3.13.73.0
Total Income129.0112.3112.3
Expenses
+ Cost of Materials Consumed61.037.440.9
+ Purchases of Stock-in-Trade1.30.00.0
+ Changes in Inventories-4.9-1.51.0
+ Employee Benefit Expense8.410.111.4
+ Finance Costs0.62.13.6
+ Depreciation & Amortisation6.19.610.5
+ Other Expenses18.223.421.0
Total Expenses90.881.088.3
EBITDA41.839.235.0
EBIT35.729.624.5
Profit
Pretax Income38.231.324.0
+ Current Tax9.38.05.6
+ Deferred Tax0.7-0.00.5
Tax Expense10.18.26.2
Net Income28.123.117.8
+ Other Comprehensive Income0.1-0.00.0
Total Comprehensive Income28.223.117.8
Per Share
Basic EPS22.3517.9813.84
Diluted EPS22.3517.9813.84
Derived — Gross Profit (Revenue − Materials − Purchases − Δ Inventories)
Gross Profit68.472.767.4
Gross Margin %54.3766.9761.68
As filed, sign as filed — read the label, not the sign. A line appears only when the company tagged that concept in at least one period shown, so depth follows the filer: pre-Ind-AS, insurance and NBFC blocks stay hidden unless they were actually reported. Alternate tags for the same idea (e.g. two spellings of a deferred-tax element) are kept as separate lines rather than merged, because merging them would be a guess. Ratios, per-share figures and counts render as raw numbers, not ₹ Crore. No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreementXBRL cross-verified ✓ 85%.